Cognito Therapeutics raises $105M to push Alzheimer's headset toward FDA clearance
What's the deal? Cambridge-based Cognito Therapeutics has closed a $105 million Series C to advance Spectris, its wearable device for Alzheimer's disease, toward FDADealroom has a profile for this one. Try Dealroom → clearance.
The round was led by Morningside Ventures, IAG Capital PartnersDealroom has a profile for this one. Try Dealroom →, and Starbloom CapitalDealroom has a profile for this one. Try Dealroom →, bringing the company's total raised to $233 million.
Spectris works by delivering gamma-frequency light and sound through a headset-like device worn for one hour a day, based on research from MITDealroom has a profile for this one. Try Dealroom →.
Why now? Timing is tight and deliberate. Top-line results from Cognito's 673-person pivotal trial are expected in August 2026, with an FDA submission planned by year-end and a potential market launch in 2027.
The Series C also includes mechanisms to unlock additional capital upon receipt of trial data — giving Cognito a staged funding structure tied directly to clinical milestones.
The raise comes as the two approved Alzheimer's antibody drugs, from Eli LillyDealroom has a profile for this one. Try Dealroom → and the EisaiDealroom has a profile for this one. Try Dealroom →-BiogenDealroom has a profile for this one. Try Dealroom → partnership, have disappointed: both carry risks of brain swelling and have fallen short of sales expectations, leaving a gap in the market for safer, more accessible alternatives.
What could go wrong? The pivotal trial is the critical gating factor. A previous 60-person study suggested Spectris could slow functional decline, but was too small to demonstrate efficacy. If the larger trial fails to deliver clear results, the FDA submission timeline collapses.
Even with positive data, the commercial path is uncertain. Spectris doesn't fit neatly into existing payment or care frameworks, and CEO Christian HowellDealroom has a profile for this one. Try Dealroom → has acknowledged the company will need to build new reimbursement models with payers and health systems from scratch. An early projection of $7.5 billion in peak sales has quietly disappeared from recent materials.
The signal: Spectris represents a broader bet on non-drug approaches to neurodegeneration — a category that has attracted little regulatory or commercial traction historically, but is gaining ground as drug-based treatments prove difficult to scale safely. The FDA's breakthrough device designation, which Spectris holds, creates a faster regulatory lane and access to an emerging coverage pathway for new technologies.
If the trial data holds, Cognito could become the first device-based Alzheimer's treatment on the market — and a proof of concept for a wave of neurostimulation startups working on similar approaches, including Sinaptica TherapeuticsDealroom has a profile for this one. Try Dealroom → and NeuroEMDealroom has a profile for this one. Try Dealroom →.
Sources:
Business Wire
Longevity.Technology
Mass Device
BioXconomy
Business Journals
STAT News
Image credit:
Cognito Therapeutics
J.V.
